DiGiandomenico, PhD - Scientist II, Keller, BS - Research Associ- H. Duong, BS - Student Sellman, PhD- Principal Scientist, C. Tkaczyk, PhD - Sr. Scientist, M.

168 SCIENTIFIC SESSIONS September 9-12 | ------------------------------------------------------------------------ 195 V Symposium Influenza: Beyond the Headlines Tuesday, 11:15 a.m.–12:45 p.m. . . . . . . . . . . . . . . . . . Room 130 UAN: 0391-9999-12-135-L04-P Conveners: Guy Boivin, MD - Professor Laval Univ., Quebec, Canada. Vincent Racaniello, PhD - Professor Columbia Univ., New York, NY. Speakers: 11:15 a.m. 1731 Host Genetics of Severe Influenza Kenneth Baillie, BSc MRCP FRCA - Clinical Lecturer The Roslin Inst., Univ. of Edinburgh, Midlothian, United Kingdom. 11:45 a.m. 1732 H5N1 Influenza Viruses in Asia and Middle-East: Still a Threat? Malik Peiris, MBBS, PhD - Professor The Univ. of Hong Kong, Hong Kong. 12:15 p.m. 1733 Emergence of an Animal-Origin Influenza A H3N2 Virus in the US Lyn Finelli, PhD - Lead, Influenza Surveillance and Outbreak Response, Influenza Division CDC, Atlanta, GA. Objectives: Upon completion of this Symposium Session, the participant should be able to: Describe the epidemiological features of selected influenza virus threats; Assess the mechanisms responsible for severe influenza diseases; Identify risk factors for severe influenza infections; and Discuss potential therapeutic and prophylactic modalities for specific influenza variants. Intended Audience: Infectious diseases specialists, virologists, clinical microbiologists, and pediatricians. Level: IntermediateAdvanced ------------------------------------------------------------------------ 196 B Slide Session Novel Antibody Therapy of Difficult Infections Tuesday, 11:15 a.m.–12:45 p.m. . . . . Esplanade Ballroom 310 UAN: 0391-9999-12-136-L04-P Moderators: Liise-anne Pirofski, MD - Chief, Division of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center Albert Einstein Coll. of Med., Bronx, NY. Arturo Casadevall, MD, PhD - Professor of Microbiology and Immunology and Medicine; Chair, Department of Microbiology and Immunology Albert Einstein Coll. of Med. of Yeshiva Univ., Bronx, NY. Objectives: Upon the completion of this Slide Session, the particpant should be able to: Define antibody therapy; Discuss the rationale for use of antibody therapy; Discuss mechanisms by which antibody therapies work; and Discuss the pathogens for which antibody therapies are being developed. Presentations: 11:15 a.m. B-1734 Controlling Pseudomonas aeruginosa Infections Using a Novel Anti-PslPcrV Multi-Specific Antibody Approach A. DiGiandomenico, PhD - Scientist II, A. Keller, BS - Research Associ- ate II, C. Gao, PhD - Associate Scientist II, J. Hilliard, PhD - Scientist II, M. Camara, MS - Associate Scientist I, P. Warrener, MS - Scientist II, G. Rainey, PhD - Scientist II, C. Gao, PhD - Fellow, N. Dimasi, PhD - Senior Scientist, B. Sellman, PhD - Principal Scientist, C. Stover, PhD - Senior Director; Med- Immune, LLC, Gaithersburg, MD. 11:30 a.m. B-1735 Efficacy of Human Intravenous Immunoglobulin IVIG for the Treatment of Lethal Necrotizing Pneumonia Caused by Hypervirulent Community-Associated Methicillin-Resistant Staphylococcus aureus

A. H. Duong, BS - Student

1 , C. Badiou, PhD - Researcher 2 , H. N. Le, BA - Student 1 , H. F. Chambers, MD - Professor 1 , B. A. Diep, PhD - Assistant Professor 1 , G. Lina, MD - Professor 2 ; 1 Univ. California San Francisco, CA, 2 Univ. Lyon, Lyon, France. 11:45 a.m. B-1736 Anti-Alpha Toxin mAb Reduces CA-MRSA Disease Severity an a Murine Dermonecrosis Model Through a Modulation of the Inflammatory Response

B. Sellman, PhD- Principal Scientist, C. Tkaczyk, PhD - Sr. Scientist, M.

Hamilton, MS - Associate Scientist, A. Datta, MD - Pathologist, T. O’Day, BS - Statistician, L. Hua, PhD - Scientist, A. Barnes, BS - Associate Scientist, C. Stover, PhD - Sr. Director; MedImmune, LLC, Gaithersburg, MD. 12:00 p.m. B-1737 Evaluation of Anti-Alpha Toxin mAb in Adjunctive Therapy with Vancomycin in a MRSA-Induced Mouse Pneumonia Model J. J. Hilliard, PhD- Scientist II, R. Zinsou, MS - Associate Scientist I, C. Tkaczyk, PhD - Senior Scientist, L. Hua, PhD - Scientist I, Y. Shi, BS - As- sociate Scientist I, L. Cheng, DVM - Pathologist, B. Sellman, PhD - Principal Scientist, C. K. Stover, PhD - Senior Director; MedImmune, LLC, Gaithers- burg, MD. 12:15 p.m. B-1738 Improved Antibody Therapies for the Treatment of Clostridium difficile Infection

D. P. Humphreys, PhD - Director, A. Moore, PhD - Senior Scientist, N.